ArticleACS pharmacology & translational science2025

Targeting of a Bile Acid Receptor, Takeda G Protein Receptor 5 [TGR5], by a Novel First-in-Class Competitive Antagonist, SBI-364, Diminishes Hepatic and Renal Cystogenesis in Polycystic Liver and Kidney Disease.

Tetyana Masyuk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.